In 2023, there will be significant interest in glial cell models, neuroinflammatory biomarkers, and optimizing approaches to target LRKK2, TREM2, and other neurological indications. As a result, large biopharmaceutical companies are expanding their departments in these areas. The 5th Annual Neuroimmunology Drug Development meeting will bring togeth
25-27 April 2023